Short answer
CASTLE BIOSCIENCES INC (CSTL) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $104M (up 20.1% year over year) with net income of −$2M.
Q2 2026 key financials · XBRL
- Revenue
- $104M
- +20.1% YoY · +23.7% QoQ
- Net income
- −$2M
- −145.5% YoY · +85.8% QoQ
- Operating margin
- -3.0%
- EPS (diluted)
- −$0.06
- −137.5% YoY · +87.8% QoQ
Source: XBRL data from the CASTLE BIOSCIENCES INC (CSTL) Q2 2026 10-Q on SEC EDGAR. USD.
CASTLE BIOSCIENCES INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Test reports 30,822, up 16% YoY, driven by TissueCypher volume growth of 63%
- TissueCypher strongest line, 14,988 reports versus DecisionDx-UM’s 482
- AdvanceAD-Tx generated approximately 1,000 orders during limited access launch
- Pittsburgh laboratory expansion supporting TissueCypher capacity and future growth
- Phased AdvanceAD-Tx availability planned throughout remainder of 2026 amid macroeconomic uncertainties
Risk Factors
- Newly heightened geopolitical risk: U.S.-Iran conflict since February 2026, with Strait of Hormuz closure risk threatening energy and shipping continuity
- Most material reimbursement update: DecisionDx-SCC became noncovered under Novitas’ LCD effective April 24, 2025
- Regulatory risk: DecisionDx-SCC reconsideration remains pending, with MolDX placing the test on a waiting list
- Near-term revenue concentration: Majority expected from DecisionDx-Melanoma and TissueCypher as DecisionDx-SCC revenue declines in 2026
- Financial risk: Six-month net loss reached $16.6 million, increasing accumulated deficit to $240.9 million
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CASTLE BIOSCIENCES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.